These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16418689)

  • 41. ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation.
    Taegtmeyer AB; Breen JB; Smith J; Burke M; Leaver N; Pantelidis P; Lyster H; Yacoub MH; Barton PJ; Banner NR
    Transplantation; 2010 Jan; 89(1):75-82. PubMed ID: 20061922
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
    Masuda S; Inui K
    Pharmacol Ther; 2006 Oct; 112(1):184-98. PubMed ID: 16759707
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients.
    Liu F; Ou YM; Yu AR; Xiong L; Xin HW
    Genet Test Mol Biomarkers; 2017 Nov; 21(11):663-673. PubMed ID: 28945481
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.
    van Gelder T; van Schaik RH; Hesselink DA
    Nat Rev Nephrol; 2014 Dec; 10(12):725-31. PubMed ID: 25247332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation.
    Szekeres T; Haushofer A
    Pharmacogenomics; 2005 Mar; 6(2):163-8. PubMed ID: 15882134
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation.
    Min S; Papaz T; Lafreniere-Roula M; Nalli N; Grasemann H; Schwartz SM; Kamath BM; Ng V; Parekh RS; Manlhiot C; Mital S
    Pediatr Transplant; 2018 Nov; 22(7):e13285. PubMed ID: 30178515
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.
    Tang JT; Andrews LM; van Gelder T; Shi YY; van Schaik RH; Wang LL; Hesselink DA
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):555-65. PubMed ID: 27010623
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
    Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacogenetics of calcineurin inhibitors in renal transplantation.
    Coto E; Tavira B
    Transplantation; 2009 Aug; 88(3 Suppl):S62-7. PubMed ID: 19667964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients.
    Renders L; Frisman M; Ufer M; Mosyagin I; Haenisch S; Ott U; Caliebe A; Dechant M; Braun F; Kunzendorf U; Cascorbi I
    Clin Pharmacol Ther; 2007 Feb; 81(2):228-34. PubMed ID: 17192769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child.
    Zhao W; Baudouin V; Fakhoury M; Storme T; Deschênes G; Jacqz-Aigrain E
    Transplantation; 2012 Apr; 93(7):e29-30. PubMed ID: 22450597
    [No Abstract]   [Full Text] [Related]  

  • 52. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
    Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
    Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacogenomics of immunosuppressive drug metabolism.
    Fredericks S; Holt DW
    Curr Opin Nephrol Hypertens; 2003 Nov; 12(6):607-13. PubMed ID: 14564197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
    Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
    Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
    Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
    Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of genetic polymorphism of cytochrome P450 3A and transporter gene on pharmacokinetics of tacrolimus, a calcineurin inhibitor].
    Niwa T; Shiraga T; Omura M; Kondo T; Kuroda M; Takagi A
    Nihon Yakurigaku Zasshi; 2006 Dec; 128(6):395-404. PubMed ID: 17167213
    [No Abstract]   [Full Text] [Related]  

  • 57. Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms.
    Miyata Y; Akamatsu N; Sugawara Y; Kaneko J; Yamamoto T; Suzuki H; Arita J; Sakamoto Y; Hasegawa K; Tamura S; Kokudo N
    Ann Transplant; 2016 Aug; 21():491-9. PubMed ID: 27503662
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
    Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
    Díaz-Molina B; Tavira B; Lambert JL; Bernardo MJ; Alvarez V; Coto E
    Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
    Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
    Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.